Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Abstract CDK4/6 inhibitors (CDK4/6i) improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Tim Kong, Alex Mabry, Maureen Highkin, Anthony Z. Wang, Jeremy Hoog, Zhanfang Guo, Adrian Gonzales-Gonzales, Shana Thomas, Yingduo Song, Feng Gao, Mateusz Opyrchal, Lindsay Peterson, Foluso Ademuyiwa, Julie Margenthaler, Rebecca Aft, Katherine Glover-Collins, Leslie Nehring, Yu Tao, Souzan Sanati, Ian S. Hagemann, Fouad Boulos, Matthew Holt, Li Ding, Wenge Zhu, Stephen T. Oh, Jianxin Wang, Agnieszka K. Witkiewicz, Erik S. Knudsen, Ron Bose, Jason D. Weber, Matthew Goetz, Donald Northfelt, Jingqin Luo, Cynthia X. Ma
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2026-01-01
Schriftenreihe:	Nature Communications
Online-Zugang:	https://doi.org/10.1038/s41467-026-68570-6
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!